Camurus announces strong first quarter demand for Buvidal®
Camurus announced today continued strong revenue growth driven by increasing demand for weekly and monthly Buvidal® for the treatment of opiod dependence in EU and Australia.
Large increase in the number of patients treated with weekly and monthly Buvidal® for opioid dependence. Camurus reiterates its 2020 outlook, with sales and total revenues expected to reach the higher end of previous guidance.